Showing results (141-150 of 380) with videos related to

Sort By:
Pageof 38
American Journal of Hematology|July 23, 2020
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patientsGautam Borthakur, Zhihong Zeng, Jorge E Cortes, et al.
Cancer|June 1, 2019
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemiaKamal Chamoun, Hagop M Kantarjian, Xuemei Wang, et al.
Cancer|December 22, 2017
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phaseKoji Sasaki, Hagop Kantarjian, Susan O'Brien, et al.
American Journal of Hematology|May 29, 2015
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcomeTalha Badar, Aditya Shetty, Carlos Bueso-Ramos, et al.
Blood Advances|January 21, 2022
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVADNaveen Pemmaraju, Nathaniel R Wilson, Guillermo Garcia-Manero, et al.
Cancer|March 18, 2025
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemiaAlexandre Bazinet, Alex Bataller, Tapan Kadia, et al.
American Journal of Hematology|November 5, 2014
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemiaTapan M Kadia, Hagop M Kantarjian, Deborah A Thomas, et al.
Blood Neoplasia|June 2, 2025
Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMMLSamuel Urrutia, Prithviraj Bose, Yesid Alvarado, et al.
Frontiers in Oncology|May 27, 2021
Immunotherapy in Acute Myeloid Leukemia: Where We StandAlessandro Isidori, Claudio Cerchione, Naval Daver, et al.
Leukemia & Lymphoma|September 5, 2022
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemiaYue Wei, Hong Zheng, Pamela Pennington Lockyer, et al.
Pageof 38